Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dutasteride (Primary) ; Tamsulosin (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Registrational; Therapeutic Use
  • Acronyms CombAT
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 13 Sep 2021 Data (n=9167) from studies (ARIA3001,ARIA3002 and ARIB3003 and CombAT) used to develop a risk calculator to Predict Changes in International Prostate Symptom Score and Risk of Retention or Surgery in Benign Prostatic Hyperplasia Patients with Moderate-Severe Symptoms at Risk of Disease Progression Receiving Placebo, Dutasteride, Tamsulosin, or Combination Therapy presented at the 116th Annual Meeting of the American Urological Association
    • 28 Nov 2020 Results of pooled meta-analysis from six clinical studies: ARIA3001, ARIA3002, ARI40002, ARIB3003, CombAT and CONDUCT published in the British Journal of Clinical Pharmacology
    • 26 Jul 2020 Results (n=10238) of pooled analysis of 6 studies (ARIA3001, ARIA3002, ARI40002, ARIB3003, CombAT, CONDUCT) assessing impact of early vs delayed initiation of dutasteride/tamsulosin combination therapy in benign prostatic hyperplasia patients with moderate to severe lower urinary tract symptoms, presented at the 35th Congress of the European Association of Urology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top